Australian Family Physician
Australian Family Physician


Volume 42, Issue 11, November 2013

Rheumatoid arthritis

Ying Pan Janice Charles Helena Britt
Download article
Cite this article    BIBTEX    REFER    RIS

Rheumatoid arthritis was managed 716 times in the two-year period, at four in every 1000 encounters, and made up 0.2% of all problems managed. About three-quarters of patients (77.5%) at RA encounters were female. The age and sex-specific rates showed a significantly higher rate of RA management for patients aged 65–74 years (0.8 per 100 encounters), and females were managed for the condition almost two and a half times more often than males (Figure 1).

Figure 1. Age and sex-specific rates of rheumatoid arthritis

Figure 1. Age and sex-specific rates of rheumatoid arthritis (error bars indicate 95% confidence interval)

Management of RA

There were 101 medications prescribed, supplied or advised for every 100 RA problems managed. Methotrexate was the most common, recorded for 23% of RA problems and accounting for 22% of medications for RA. Hydroxychloroquine made up 8% of these medications and prednisolone 7%.

Other treatments were recorded at a rate of 26 per 100 RA problems managed and consisted of procedures (a high proportion of which were injections) and clinical treatments (mainly advice on medication and counselling about RA). Referrals were provided at a higher than average rate for BEACH (15 per 100 RA problems, compared with 9 per 100 total problems), and most were to rheumatologists. Pathology tests were ordered at almost double the average rate (67 per 100 RA problems, compared with 31 per 100 total problems), but imaging orders were less common than average (Table 1).

Table 1. Treatments for rheumatoid arthritis
TreatmentNumberRate per 100 RA problemsProportion of each treatment (%)
Medications 723 101.0 100.0
Methotrexate 161 22.5 22.3
Hydroxychloroquine 61 8.5 8.4
Prednisolone 52 7.3 7.2
Paracetamol 48 6.7 6.6
Oxycodone 44 6.1 6.1
Other treatments 188 26.3 100.0
Injections 68 9.5 36.1
Medication advice 32 4.5 17.0
Counselling 29 4.1 15.4
Referrals 104 14.5 100.0
Rheumatologist 62 8.7 59.6
Pathology tests 477 66.6 100.0
Full blood count 113 15.8 23.7
C-reactive protein 73 10.2 15.3
Imaging 32 4.5 100.0

Competing interests: None.
Provenance and peer review: Commissioned; not peer reviewed.


The authors thank the GP participants in the BEACH program, and all members of the BEACH team. Funding contributors to BEACH from April 2011 to March 2013: Australian Government Department of Health and Ageing; AstraZeneca Pty Ltd (Australia); CSL Biotherapies Pty Ltd; Merck, Sharp and Dohme (Australia) Pty Ltd; National Prescribing Service; Novartis Pharmaceuticals Australia Pty Ltd; Pfizer Australia Pty Ltd. BEACH is approved by the Human Research Ethics Committee of the University of Sydney.

  1. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81. Search PubMed
  2. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793–800. Search PubMed
  3. Harrison C, Britt H, Miller G, Henderson J. Prevalence of chronic conditions in Australia. PLoS ONE 2013;8:e67494. Search PubMed
Download article PDF


Australian Family Physician RACGP

Printed from Australian Family Physician - https://www.racgp.org.au/afp/2013/november/rheumatoid-arthritis
© The Australian College of General Practitioners www.racgp.org.au